The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.

@article{Haass2008TheMP,
  title={The mitogen-activated protein/extracellular signal-regulated kinase kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel.},
  author={Nikolas K. Haass and Katrin Sproesser and Thiennga K. Nguyen and Rooha Contractor and C Angelica Medina and Katherine L Nathanson and Meenhard Herlyn and Keiran Sm Smalley},
  journal={Clinical cancer research : an official journal of the American Association for Cancer Research},
  year={2008},
  volume={14 1},
  pages={230-9}
}
PURPOSE Disseminated melanoma is highly therapy resistant. The finding that 66% of melanomas harbor the activating BRAF(V600E) mutation has raised expectations for targeting the Ras/RAF/mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK pathway in melanoma. This study addresses the anti-melanoma activity of the MEK inhibitor AZD6244 (ARRY-142886). EXPERIMENTAL DESIGN We recently have shown that growing melanoma cells as three-dimensional collagen… CONTINUE READING

6 Figures & Tables

Connections & Topics

Mentioned Connections BETA
melanomaMay be treated bydocetaxel
Inhibition of MEK is cytostatic as a monotherapy in melanoma , but cytotoxic when combined with docetaxel .
AZD 6244Has lab numberARRY 142886
The finding that 66% of melanomas harbor the activating BRAF(V600E ) mutation has raised expectations for targeting the Ras / RAF / mitogen - activated protein ( MAP)/extracellular signal - regulated kinase ( ERK ) kinase ( MEK)/ERK pathway in melanoma . This study addresses the anti - melanoma activity of the MEK inhibitor AZD6244 ( ARRY-142886 ) .
The mitogen - activated protein / extracellular signal - regulated kinase kinase inhibitor AZD6244 ( ARRY-142886 ) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel .
The finding that 66% of melanomas harbor the activating BRAF(V600E ) mutation has raised expectations for targeting the Ras / RAF / mitogen - activated protein ( MAP)/extracellular signal - regulated kinase ( ERK ) kinase ( MEK)/ERK pathway in melanoma . This study addresses the anti - melanoma activity of the MEK inhibitor AZD6244 ( ARRY-142886 ) .
The mitogen - activated protein / extracellular signal - regulated kinase kinase inhibitor AZD6244 ( ARRY-142886 ) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel .
All Topics